Ligand Pharmaceuticals Incorporated
Every calculator, already run for LGND
Open the full toolkit →You have the numbers on LGND. Get the argument.
A written report on which of these readings actually decide the outcome for Ligand Pharmaceuticals Incorporated, what has to stay true for the price to work, and the specific thing that would break it. The first one is free.
Key market data
Analyst consensus
10 analysts covering LGNDAnalyst Price Target Disagreement for Ligand Pharmaceuticals Incorporated
Wall Street's bull case implies +38% from the current price; the bear case implies -13%. A 50% spread signals high analyst disagreement — run your own DCF to anchor on fundamentals rather than street consensus.
Ownership & short interest
Insider Trading Activity for LGND
| Insider | Role | Type | Shares | Price | Value | Date | Filing |
|---|---|---|---|---|---|---|---|
About Ligand Pharmaceuticals Incorporated
Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, develops and licenses biopharmaceutical assets worldwide. It offers Pradefovir, Posaconazole, Voriconazole, CAPVAXIVE, NOXAFIL, MenFive, and ZELSUVMI for infectious disease; EVOMELA and KYPROLIS for multiple myeloma; FILSPARI for the treatment of immunoglobulin a nephropathy; PNEUMOSIL, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia in children; and QARZIBA to treat neuroblastoma. The company also provides Teriparatide injection product for osteoporosis; RYLAZE, a recombinant erwinia asparaginase for acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; TZIELD, a…
LGND — frequently asked
Is LGND a buy right now?
Wall Street's consensus rating on Ligand Pharmaceuticals Incorporated is none across 10 analysts, with a mean price target of $342.82 (+21% vs. the current $283.49). Ratings are a starting point — run the DCF and check the financial-health readings above before deciding.
Is LGND overvalued?
LGND trades at 29.2x trailing earnings, against a DCF fair value of $161 per share. The current price implies 13% annual free-cash-flow growth for a decade. Open the DCF or reverse-DCF tool to change the assumptions and see the range.
When is LGND's next earnings date?
Ligand Pharmaceuticals Incorporated is next scheduled to report earnings around Nov 5, 2026. A full LGND research report from Basis Report covers the setup into that print — estimates, the beat/miss record, and what would move the thesis.
What is the analyst price target disagreement for Ligand Pharmaceuticals Incorporated?
Analysts covering Ligand Pharmaceuticals Incorporated (LGND) range from a bear-case target of $247.00 to a bull-case high of $390.00, with a mean consensus target of $342.82 across 11 analysts. The spread of $143.00 (50% of the current price) indicates high disagreement on the outlook. Run the DCF calculator to build your own estimate independent of street consensus.
Compare Ligand Pharmaceuticals Incorporated against related stocks
Explore additional stock overview pages and jump directly into full report generation for each symbol.
Sector peers
Most-followed names in the same sector.
Nearby tickers
Additional public equities from our tracked universe.
Market leaders
Large-cap symbols investors frequently compare.
Investor Guides For Ligand Pharmaceuticals Incorporated
Start with the evergreen guides that matter most for Healthcare, then move back into the ticker page when you want to pressure-test the framework on a live name.
Generate your full LGND research report
DCF model, five-year financials, moat assessment, a BUY/HOLD/SELL rating, and the risks that matter — on Ligand Pharmaceuticals Incorporated, in minutes. 3 free reports included with every account — no credit card required.